CRCP
HAE icon

Copper Rock Capital Partners’s Haemonetics HAE Stock Holding History

Copper Rock Capital Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-282,178
Closed -$31.9M – 80
2018
Q3 		$31.9M Sell
282,178
-126,059
-31% -$13.1M 1.98% 5
2018
Q2 		$36.5M Sell
408,237
-94,403
-19% -$7.97M 2.1% 3
2018
Q1 		$36.8M Buy
+502,640
New +$34.5M 2.2% 8

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Copper Rock Capital Partners's HAE Position: Q4 2018 in Review

Copper Rock Capital Partners sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 282,178 shares — an estimated $31.9M sold.

Copper Rock Capital Partners first reported a position in HAE in Q1 2018 and held it in 3 quarters. The position peaked at $36.8M in Q1 2018. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

  • Copper Rock Capital Partners reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
  • Copper Rock Capital Partners sold 282,178 Haemonetics shares in Q4 2018, an estimated $31.9M.
  • Copper Rock Capital Partners first reported a position in Haemonetics in Q1 2018 and held it in 3 quarters.
  • Copper Rock Capital Partners's Haemonetics position peaked at $36.8M in Q1 2018.
  • 279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Copper Rock Capital Partners's 13F filing for Q4 2018, filed 9 Jan 2019.